Recent progress in pancreatic cancer

Authors

  • Christopher L. Wolfgang MD, PhD,

    1. Associate Professor, Department of Surgery, The Johns Hopkins University School of Medicine, Baltimore, MD
    2. Associate Professor, Department of Oncology, The Sol Goldman Pancreatic Cancer Research Center, The Johns Hopkins University School of Medicine, Baltimore, MD
    3. Associate Professor, Department of Pathology, The Sol Goldman Pancreatic Cancer Research Center, The Johns Hopkins University School of Medicine, Baltimore, MD
    Search for more papers by this author
    • The first 3 authors contributed equally to this work.

  • Joseph M. Herman MD, MSc,

    1. Associate Professor, Department of Radiation Oncology and Molecular Radiation Sciences, The Johns Hopkins University School of Medicine, Baltimore, MD
    Search for more papers by this author
  • Daniel A. Laheru MD,

    1. Associate Professor, Department of Oncology, The Sol Goldman Pancreatic Cancer Research Center, The Johns Hopkins University School of Medicine, Baltimore, MD
    Search for more papers by this author
  • Alison P. Klein PhD, MHS,

    1. Associate Professor, Department of Oncology, The Sol Goldman Pancreatic Cancer Research Center, The Johns Hopkins University School of Medicine, Baltimore, MD
    2. Associate Professor, Department of Pathology, The Sol Goldman Pancreatic Cancer Research Center, The Johns Hopkins University School of Medicine, Baltimore, MD
    3. Associate Professor Department of Epidemiology, the Bloomberg School of Public Health, Johns Hopkins University, Baltimore, MD
    Search for more papers by this author
  • Michael A. Erdek MD,

    1. Associate Professor, Department of Anesthesiology and Critical Care Medicine, The Johns Hopkins University School of Medicine, Baltimore, MD
    Search for more papers by this author
  • Elliot K. Fishman MD, FACR,

    1. Professor, Department of Radiology, The Johns Hopkins University School of Medicine, Baltimore, MD
    Search for more papers by this author
  • Ralph H. Hruban MD

    1. Professor, Department of Pathology, The Sol Goldman Pancreatic Cancer Research Center, The Johns Hopkins University School of Medicine, Baltimore, MD
    2. Professor, Department of Oncology, The Sol Goldman Pancreatic Cancer Research Center, The Johns Hopkins University School of Medicine, Baltimore, MD.
    Search for more papers by this author

  • DISCLOSURES: Supported by National Institutes of Health grants P30 CA006973 and P50 CA62924. Dr. Hruban and Dr. Klein receive royalty payments from Myriad Genetics for the PALB2 invention.

Corresponding author: Ralph H. Hruban, MD, Department of Pathology and Oncology, The Sol Goldman Pancreatic Cancer Research Center, The Johns Hopkins University School of Medicine, Weinberg Room 2242, 401 North Broadway, Baltimore, MD 21231; rhruban@jhmi.edu

Abstract

Answer questions and earn CME/CNE

Pancreatic cancer is currently one of the deadliest of the solid malignancies. However, surgery to resect neoplasms of the pancreas is safer and less invasive than ever, novel drug combinations have been shown to improve survival, advances in radiation therapy have resulted in less toxicity, and enormous strides have been made in the understanding of the fundamental genetics of pancreatic cancer. These advances provide hope but they also increase the complexity of caring for patients. It is clear that multidisciplinary care that provides comprehensive and coordinated evaluation and treatment is the most effective way to manage patients with pancreatic cancer. CA Cancer J Clin 2013;63:318-348. ©2013 American Cancer Society.

Ancillary